Sironax Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors reported to be useful for the treatment of ulcerative colitis, Crohn's disease, psoriasis, rheumatoid arthritis, amyotrophic lateral sclerosis (ALS), Alzheimer's disease and viral infection.
Trophoblast glycoprotein, also known as 5T4, is widely expressed in several solid tumors; cluster of differentiation 47 (CD47) is an ubiquitous immune checkpoint receptor that is also overexpressed in many solid tumors as well as in hematological cancers. A Yuhan Corp. research team has presented preclinical results on YH-38560, a bispecific fusion protein that targets both 5T4 and CD4 for the potential treatment of solid tumors.
Regulatory T cells (Tregs) are known suppressors of immunity activation in the tumor microenvironment, and a high density of Tregs is tied to a poor response to cancer immunotherapy, with CCR8+ Tregs identified as being highly suppressive. Ctm Bio Co. therefore have studied the CCR8 antagonist antibody CTM-033 in preclinical cancer models.
Investigators from Immunos Therapeutics AG aimed to develop novel anticancer therapies by using a reverse rational approach from HLA class I molecules with the aim to induce autoimmunity, and they identified HLA-B*57 as a well-known genetic factor associated with superior control of viral infections through processes not linked with peptide presentation.
Constellation Pharmaceuticals Inc. has described three-prime repair exonuclease 1 (TREX1) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Simcere Pharmaceutical R&D Co. Ltd. has disclosed alkyne compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Activation of the cGAS-STING pathway activates the immune system through the production of type I interferons. There is knowledge that myeloid cell populations are among the most sensitive to STING agonism. Investigators at Takeda Pharmaceutical Co. Ltd. presented results on TAK-500, an immune stimulant antibody-drug conjugate (ISAC) composed of an antibody linked to a STING agonist for delivery to CCR2+ cells.
Immunocytokines (ICs) engage multiple mechanisms of action by the use of antibodies to deliver cytokine payloads to the surface of the same immune cell, known as cis-signaling. Researchers from Bright Peak Therapeutics AG have developed ICs by using a novel approach based on site-specific chemical conjugation of engineered cytokines to existing nonmodified antibodies.
